MetaCap

Sionna Therapeutics (SION) vs Zentalis Pharmaceuticals (ZNTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zentalis Pharmaceuticals (ZNTL) has outperformed Sionna Therapeutics (SION) over the past year, gaining 1.5% versus a loss of 93.5%. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $127.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SION-93.53%ZNTL+1.49%
+418%+150%-118%
Nov 21, 20251 yearNov 20, 2026
SION-88.70%ZNTL-29.17%
+261%+78%-105%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SION versus ZNTL key metrics
MetricSIONZNTL
Share price$2.83$1.36
Market cap$127.79M$133.64M
1-day change-4.88%0.00%
YTD return-93.13%+0.74%
1-year return-93.53%+1.49%
5-year return—-98.21%
EPS (TTM)$-2.43$-1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-75.27M$-137.06M
52-week high$54.97$6.95
52-week low$2.75$1.30
Distance from 52-week high-94.86%-80.43%
Analyst consensusholdstrong_buy
Avg. price target upside+643.36%+447.06%
Average volume1.12M1.26M
Shares outstanding45.24M98.27M
Employees59106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZNTL has outperformed SION by 95.0 percentage points over the past year.

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

About Zentalis Pharmaceuticals

ZNTL stock →

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

SION vs ZNTL FAQ

Which is bigger, Sionna Therapeutics or Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $127.79M for Sionna Therapeutics (SION).

Which stock has performed better over the past year, SION or ZNTL?

ZNTL returned +1.49% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are Sionna Therapeutics and Zentalis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons